FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125879679> ?p ?o ?g. }

• W2125879679 endingPage "817" @default.
• W2125879679 startingPage "817" @default.
• W2125879679 abstract "Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies.To determine if there is an association between early high-dose recombinant human erythropoietin treatment in preterm infants and biomarkers of encephalopathy of prematurity on magnetic resonance imaging (MRI) at term-equivalent age.A total of 495 infants were included in a randomized, double-blind, placebo-controlled study conducted in Switzerland between 2005 and 2012. In a nonrandomized subset of 165 infants (n=77 erythropoietin; n=88 placebo), brain abnormalities were evaluated on MRI acquired at term-equivalent age.Participants were randomly assigned to receive recombinant human erythropoietin (3000 IU/kg; n=256) or placebo (n=239) intravenously before 3 hours, at 12 to 18 hours, and at 36 to 42 hours after birth.The primary outcome of the trial, neurodevelopment at 24 months, has not yet been assessed. The secondary outcome, white matter disease of the preterm infant, was semiquantitatively assessed from MRI at term-equivalent age based on an established scoring method. The resulting white matter injury and gray matter injury scores were categorized as normal or abnormal according to thresholds established in the literature by correlation with neurodevelopmental outcome.At term-equivalent age, compared with untreated controls, fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter injury (22% [17/77] vs 36% [32/88]; adjusted risk ratio [RR], 0.58; 95% CI, 0.35-0.96), white matter signal intensity (3% [2/77] vs 11% [10/88]; adjusted RR, 0.20; 95% CI, 0.05-0.90), periventricular white matter loss (18% [14/77] vs 33% [29/88]; adjusted RR, 0.53; 95% CI, 0.30-0.92), and gray matter injury (7% [5/77] vs 19% [17/88]; adjusted RR, 0.34; 95% CI, 0.13-0.89).In an analysis of secondary outcomes of a randomized clinical trial of preterm infants, high-dose erythropoietin treatment within 42 hours after birth was associated with a reduced risk of brain injury on MRI. These findings require assessment in a randomized trial designed primarily to assess this outcome as well as investigation of the association with neurodevelopmental outcomes.clinicaltrials.gov Identifier: NCT00413946." @default.
• W2125879679 created "2016-06-24" @default.
• W2125879679 creator A5001788338 @default.
• W2125879679 creator A5003667100 @default.
• W2125879679 creator A5006442525 @default.
• W2125879679 creator A5023260749 @default.
• W2125879679 creator A5035275541 @default.
• W2125879679 creator A5038452040 @default.
• W2125879679 creator A5058900131 @default.
• W2125879679 creator A5059036955 @default.
• W2125879679 creator A5084831116 @default.
• W2125879679 creator A5090449465 @default.
• W2125879679 date "2014-08-27" @default.
• W2125879679 modified "2023-10-18" @default.
• W2125879679 title "Association Between Early Administration of High-Dose Erythropoietin in Preterm Infants and Brain MRI Abnormality at Term-Equivalent Age" @default.
• W2125879679 cites W1969172610 @default.
• W2125879679 cites W1970086378 @default.
• W2125879679 cites W1972604478 @default.
• W2125879679 cites W1986333755 @default.
• W2125879679 cites W1990164686 @default.
• W2125879679 cites W1992686641 @default.
• W2125879679 cites W2000198569 @default.
• W2125879679 cites W2020591797 @default.
• W2125879679 cites W2020885105 @default.
• W2125879679 cites W2031420920 @default.
• W2125879679 cites W2039547059 @default.
• W2125879679 cites W2043480430 @default.
• W2125879679 cites W2063354453 @default.
• W2125879679 cites W2064896583 @default.
• W2125879679 cites W2068318662 @default.
• W2125879679 cites W2076026006 @default.
• W2125879679 cites W2076439819 @default.
• W2125879679 cites W2079141380 @default.
• W2125879679 cites W2092245612 @default.
• W2125879679 cites W2095988793 @default.
• W2125879679 cites W2097396554 @default.
• W2125879679 cites W2097760882 @default.
• W2125879679 cites W2097920866 @default.
• W2125879679 cites W2108188869 @default.
• W2125879679 cites W2110230188 @default.
• W2125879679 cites W2113996138 @default.
• W2125879679 cites W2114785548 @default.
• W2125879679 cites W2121693179 @default.
• W2125879679 cites W2123627458 @default.
• W2125879679 cites W2131329660 @default.
• W2125879679 cites W2131605045 @default.
• W2125879679 cites W2151467007 @default.
• W2125879679 cites W2156243257 @default.
• W2125879679 cites W2157799711 @default.
• W2125879679 cites W2158698668 @default.
• W2125879679 cites W2162395684 @default.
• W2125879679 cites W2169013045 @default.
• W2125879679 cites W2169191514 @default.
• W2125879679 cites W2172068794 @default.
• W2125879679 doi "https://doi.org/10.1001/jama.2014.9645" @default.
• W2125879679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25157725" @default.
• W2125879679 hasPublicationYear "2014" @default.
• W2125879679 type Work @default.
• W2125879679 sameAs 2125879679 @default.
• W2125879679 citedByCount "121" @default.
• W2125879679 countsByYear W21258796792014 @default.
• W2125879679 countsByYear W21258796792015 @default.
• W2125879679 countsByYear W21258796792016 @default.
• W2125879679 countsByYear W21258796792017 @default.
• W2125879679 countsByYear W21258796792018 @default.
• W2125879679 countsByYear W21258796792019 @default.
• W2125879679 countsByYear W21258796792020 @default.
• W2125879679 countsByYear W21258796792021 @default.
• W2125879679 countsByYear W21258796792022 @default.
• W2125879679 countsByYear W21258796792023 @default.
• W2125879679 crossrefType "journal-article" @default.
• W2125879679 hasAuthorship W2125879679A5001788338 @default.
• W2125879679 hasAuthorship W2125879679A5003667100 @default.
• W2125879679 hasAuthorship W2125879679A5006442525 @default.
• W2125879679 hasAuthorship W2125879679A5023260749 @default.
• W2125879679 hasAuthorship W2125879679A5035275541 @default.
• W2125879679 hasAuthorship W2125879679A5038452040 @default.
• W2125879679 hasAuthorship W2125879679A5058900131 @default.
• W2125879679 hasAuthorship W2125879679A5059036955 @default.
• W2125879679 hasAuthorship W2125879679A5084831116 @default.
• W2125879679 hasAuthorship W2125879679A5090449465 @default.
• W2125879679 hasBestOaLocation W21258796791 @default.
• W2125879679 hasConcept C126322002 @default.
• W2125879679 hasConcept C126838900 @default.
• W2125879679 hasConcept C142724271 @default.
• W2125879679 hasConcept C143409427 @default.
• W2125879679 hasConcept C187212893 @default.
• W2125879679 hasConcept C204787440 @default.
• W2125879679 hasConcept C27081682 @default.
• W2125879679 hasConcept C2778376644 @default.
• W2125879679 hasConcept C2778534260 @default.
• W2125879679 hasConcept C2778621155 @default.
• W2125879679 hasConcept C2779234561 @default.
• W2125879679 hasConcept C2781192897 @default.
• W2125879679 hasConcept C54355233 @default.
• W2125879679 hasConcept C71924100 @default.
• W2125879679 hasConcept C86803240 @default.
• W2125879679 hasConceptScore W2125879679C126322002 @default.

• next